# Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-dose-escalation-of-tofacitinib-in-refractory-anti-mda5/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Tomoaki Ida,Shunsuke Furuta,Asuka Takayama,Jun Tamura,Yuki Hayashi,Kazuya Abe,Syunjiro Kurihara,Junichi Ishikawa,Taro Iwamoto,Kei Ikeda,Kotaro Suzuki,Hiroshi Nakajima |
| Citations | 57 |
| DOI | 10.1136/rmdopen-2022-002795 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://rmdopen.bmj.com/content/rmdopen/9/1/e002795.full.pdf |
| OpenAlex ID | https://openalex.org/W4313406819 |
| PMID | 36593080 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Taro Iwamoto](https://scholariq.org/researchers/taro-iwamoto/)

## Paper primary topic

- [Inflammatory Myopathies and Dermatomyositis](https://scholariq.org/topics/inflammatory-myopathies-and-dermatomyositis/)

## Paper topics

- [Inflammatory Myopathies and Dermatomyositis](https://scholariq.org/topics/inflammatory-myopathies-and-dermatomyositis/)
- [Eosinophilic Disorders and Syndromes](https://scholariq.org/topics/eosinophilic-disorders-and-syndromes/)
- [Cutaneous lymphoproliferative disorders research](https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.